Skip to content

Augmentation of Meniscal Repair With Marrow Stimulation Techniques (Microfractures)

Augmentation of Meniscal Repair With Bone Marrow Stimulation Techniques (Microfractures): a Double Blind, Prospective, Randomized Clinical Trial of Efficacy and Safety.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02323490
Acronym
men_micro
Enrollment
40
Registered
2014-12-23
Start date
2013-08-19
Completion date
2018-04-30
Last updated
2018-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meniscus Lesion

Keywords

meniscus repair, bone marrow stimulation

Brief summary

This study will compare meniscal healing augmented or without augmentation with bone marrow stimulation techniques The assessments will include validated, disease specific, patient oriented outcome measures, second look arthroscopy during second step ACL reconstruction. Results of this study will help ascertain whether microfractures improve meniscal healing rates.

Detailed description

The role of meniscal in the knee integrity is pivotal and lack or partial role of the meniscus increases rate of joint degeneration. Partial meniscal removal is the most popular procedure and meniscal repair remain in minority of arthroscopic surgeries. As criteria of inclusion to meniscal repair are very rough, still success rates of meniscal repair remain in the 60-80% range for isolated repairs. This rate is greater when performed with ACL reconstruction. We believe that augmentation with bone marrow stimulation techniques will induce more complete and possibly faster healing.

Interventions

PROCEDUREwith microfractures

following meniscal repair, microfractures will be created on the intercondylar and outer part of femoral condyle (outside of joint surface), lateral or medial, respectively

PROCEDUREwithout microfractures

standard procedure meniscal repair without augmentation.

Sponsors

Centre of Postgraduate Medical Education
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* Complete vertical longitudinal tear \> 10 mm in length * Tear located in the vascular portion of the meniscus, only in red-white zone * Unstable peripheral tear * Single tear of the medial and/or lateral meniscus * Meniscal injury 1 -18 month prior surgery * Planned second step arthroscopy (ACL reconstruction) * Skeletally mature patients 18-55 years of age

Exclusion criteria

* discoid meniscus * arthritic changes (Kellgren Lawrence scale \>2) * non repairable meniscus * degenerative or presence of crystals in meniscus * concomitant procedure (acl reconstruction, microfracturing, trephination) * inflammatory diseases (i.e. rheumatoid arthritis)

Design outcomes

Primary

MeasureTime frameDescription
Second look arthroscopy (assessment of meniscal healing integrity during second look)8-18 weeksThe primary outcome measures will be assessment of meniscal healing integrity during second look arthroscopy 3-5 months post repair.

Secondary

MeasureTime frameDescription
Visual Analog Scale6 weeks, 12 weeks, 6mts, 1yr post op, 2yrs post op, 3 yrs post opPain Visual Analog Scale.
Knee injury and Osteoarthritis Outcome Score scale6 weeks, 12 weeks, 6mts, 1yr post op, 2yrs post op, 3 yrs post opKnee injury and Osteoarthritis Outcome Score
International Knee Documentation Committee - Subjective Knee Evaluation Form6 weeks, 12 weeks, 6mts, 1yr post op, 2yrs post op, 3 yrs post opInternational Knee Documentation Committee - Subjective Knee Evaluation Form
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)6 weeks, 12 weeks, 6mts, 1yr post op, 2yrs post op, 3 yrs post opWestern Ontario and McMaster Universities Osteoarthritis Index (WOMAC)

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026